Pfizer Files Lawsuit Against Novo: Alleges Competitor Engaged in Antitrust Scheme to Dominate Obesity Market

Bitget App

Trade smarter

Bitget

News

Markets

Pfizer Files Lawsuit Against Novo: Alleges Competitor Engaged in Antitrust Scheme to Dominate Obesity Market

Bitget-RWA2025/11/04 13:12

By:Bitget-RWA

- Pfizer sues Novo Nordisk and Metsera in Delaware courts, alleging anticompetitive tactics to block its $7.2B obesity drug acquisition. - Novo's $8.5B superior bid for Metsera's GLP-1 pipeline—valued at $5B peak sales—triggers legal claims over regulatory bypass and contract violations. - Pfizer leverages early FTC approval for its deal, seeking court orders to force a November 13 shareholder vote amid patent expiration threats. - The dispute highlights $150B obesity market stakes, with Novo defending its

Pfizer Inc. (PFE) has intensified its legal efforts to maintain its stake in the obesity-focused biotech company

Metsera

, initiating two lawsuits in Delaware against both the startup and Danish pharmaceutical giant

Novo Nordisk

. Pfizer contends that Novo’s $8.5 billion proposal is an anti-competitive tactic, asserting that its own $7.2 billion agreement—which has already received early antitrust approval from the Federal Trade Commission—is enforceable and set to close by November 13, as reported by

CryptoRank report

The dispute revolves around Metsera’s pipeline of experimental GLP-1 treatments, which feature a once-monthly injectable that has demonstrated an average 14% weight reduction in clinical trials, as well as a chemically stabilized oral version. Analysts estimate these products could achieve peak annual sales of $5 billion, according to

a NewsBytes report

Novo

, a leader in the obesity drug market with Wegovy and Ozempic, surpassed Pfizer’s offer by $1.3 billion, leading Metsera’s board to label Novo’s bid as “superior.” Pfizer argues this move breaches their merger contract and regulatory risk provisions, and claims Novo’s intricate proposal—which includes non-voting shares and a special dividend—was structured to sidestep antitrust review, according to

an FXLeaders report

Pfizer Files Lawsuit Against Novo: Alleges Competitor Engaged in Antitrust Scheme to Dominate Obesity Market image 0

Pfizer’s legal argument is based on its regulatory advantage: the FTC ended its Hart-Scott-Rodino review early on October 31, ahead of the November 7 deadline, as noted by

an AP News report

. Pfizer further alleges that Novo’s offer is an “unlawful effort by a market leader to stifle competition,” a charge Novo has called “baseless,” according to CNBC. The lawsuits aim to secure temporary restraining orders to prevent Metsera from backing out of the Pfizer agreement and to compel a shareholder vote on November 13,

STAT reports

This legal showdown highlights the growing rivalry in the obesity medication industry, which analysts expect to reach $150 billion in value by 2030. Novo, facing increased competition from Eli Lilly’s tirzepatide, is working to strengthen its drug portfolio before semaglutide patents expire. Meanwhile, Pfizer is attempting to gain entry into the sector after discontinuing its oral obesity drug candidate, danuglipron, as reported by

a TradingView post

Metsera’s investors, led by Population Health Partners and ARCH Venture Partners, are under investigation for possible collusion with Novo, according to

a PYMNTS report

. The biotech company has rejected Pfizer’s allegations as “nonsense” and has pledged to defend Novo’s offer in court, CNBC reports.

With Pfizer facing a November 5 deadline to respond to Novo’s proposal and a shareholder vote approaching, Delaware courts are poised to decide whether competitive issues or contractual commitments will take precedence in this major pharmaceutical dispute.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

- Canada unveils 2025 stablecoin framework requiring full reserves, transparent redemption, and robust risk management to align with global trends and domestic needs. - $10M Bank of Canada funding supports oversight, mirroring U.S. GENIUS Act momentum while addressing $309B market growth projected to reach $2T by 2028. - Institutions like Western Union and Tetra Digital (backed by Shopify/Wealthsimple) drive adoption, with legal clarity categorizing stablecoins as payment instruments or securities. - Frame

Bitget-RWA•2025/11/05 08:52

Sovereignty Versus Speculation: Canada Introduces Its 2025 Stablecoin Regulatory Framework

Supreme Court to Rule on Whether Trump's Tariffs Broaden Presidential Authority Beyond Congressional Limits

- The U.S. Supreme Court will decide the legality of Trump's global tariffs, potentially redefining presidential power in trade policy. - Small businesses and 12 states challenge the tariffs, arguing they exceed presidential authority and disrupt trade. - The administration defends tariffs as national security measures under IEEPA, but lower courts ruled they lack explicit legal authority. - A ruling against Trump could allow $100B in refunds, while upholding tariffs may set a precedent for expansive execu

Bitget-RWA•2025/11/05 08:52

Supreme Court to Rule on Whether Trump's Tariffs Broaden Presidential Authority Beyond Congressional Limits

Bitget and Morph Chain Establish Stablecoins as the Foundation of International Trade

- Bitget integrates Morph Chain, enabling direct USDT trading on its platform without cross-platform transfers. - The partnership expands Bitget's onchain ecosystem across Ethereum , Solana , and BNB Chain, with AI-driven trading tools. - Incentive campaigns like Onchain Challenge 25 and CandyBomb boost user engagement with BGB token rewards. - CEO Gracy Chen highlights Morph Chain's role in advancing stablecoin settlements as global commerce infrastructure. - Strategic alliances with Fasanara Capital aim

Bitget-RWA•2025/11/05 08:52